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Adoptively transferred T cells can reject large established tumors, but recurrence due to escape
variants frequently occurs. In this issue of Cancer Cell, Engels et al. demonstrate that the affinity of the
target peptide to the MHC molecule determines whether large tumors will relapse following adoptive T cell
therapy.Tumor rejection usually requires CD8+
effector T (TE) cells, which recognize com-
plexes of peptide bound to major histo-
compatibility complex (MHC) I molecules
(pMHC) on tumor cells using their T cell
receptor (TCR). The peptide is the protea-
somal degradation product of the tumor
antigen (TA). Upon recognition of pMHC,
TE cells produce effector molecules such
as perforin, IFN-g, and TNF. Although it
has long been believed that direct killing
of cancer cells by TE cells alone is respon-
sible for tumor rejection, recent studies
show that destruction of the tumor stroma
by TE cells is critical for tumor eradication,
with different mechanisms being dis-
cussed (Anders and Blankenstein, 2013;
Schreiber, 2013 and references therein).
While adoptively transferred TE cells can
reject large established tumors in experi-
mental models and in humans, tumor
recurrence after initial regression is a
major obstacle. To overcome this prob-
lem, research has focused on improving
T cell function by in vitro TCR affinity
maturation, which can result in the loss
of T cell fitness or specificity (Engels
et al., 2012; Stone et al., 2009). Little
attention has been paid to another vari-
able in the three-molecule interaction:
the affinity of the peptide to the MHC
(pMHC affinity). This is surprising, given
that the affinity of the TCR for pMHC usu-
ally lies within a narrow range (1–100 mM)
due to the complex T cell selection pro-
cess, while pMHC affinity ranges between
<1 nM to >20,000 nM due to the partly
stochastic nature of peptide sampling
(Figure 1).
In this issue of Cancer Cell, Engels
et al. (2013) addressed the impact
of pMHC affinity on tumor eradica-
tion versus relapse. In a reductionist
approach, they expressed the sameamount of different peptide antigens in
the same cancer cells. The peptide anti-
gens were derived from mouse and
human TA, presented by H-2 or HLA
molecules, respectively, and all known
as T cell epitopes. Mice with large
tumors containing abundant stroma
were then treated with TCR-transgenic
TE cells specific for the respective
pMHC complex so that the peptide was
the only variable. Therapy outcome
correlated perfectly with pMHC affinity
(Engels et al., 2013; Figure 1). pMHC
affinities <10 nM (IC50 as measured by
cell-free assays) elicited tumor rejection,
and those with >100 nM caused relapse.
Only high-affinity peptides were cross-
presented by tumor stroma cells, caus-
ing stroma destruction and thereby
preventing antigen loss variants. Pep-
tides with very low affinity to MHC (IC50
22,900 nM) could not even induce the
selection of escape variants, and anti-
gen-positive tumors progressed. In vitro
T cell kill assays did not predict rejection
epitopes. In the clinic, the reasons for
tumor relapse often remain unknown.
Based on this study, experiments in
HLA-transgenic mice with established
HLA+ syngeneic mouse tumors express-
ing human TA may allow prediction of
epitopes that should or should not be
targeted clinically. These mice can be
treated with mouse TE cells specific for
the human TA to ask whether tumors
will be rejected or recur. The human
TA-specific mouse TE cells can be gener-
ated by the transfer of TCR genes, which
can be isolated against virtually any hu-
man TA from the nontolerant repertoire,
termed TCR gene therapy (Anders and
Blankenstein, 2013; Schumacher, 2002).
Another important question addressed
by Engels et al. (2013) is: how useful areCancer Celmany of the TA epitopes currently em-
ployed clinically as therapeutic targets?
T cell epitopes of human TAs are usually
defined by autologous systems. Most
TAs are self-proteins (self-TA), and only
low-avidity T cells that survived tolerance
mechanisms are in the normal repertoire.
Typically, one or few TA epitopes for
a given MHC restriction molecule are
described. Algorithms quite accurately
predict pMHC affinity, and the IC50 values
determined by cell-free assays in Engels
et al. (2013) did not differ greatly from
the predicted values. Many of the
described T cell epitopes of human self-
TA have low affinity, e.g., IC50 for NY-
ESO157–165 (HLA-A*02:01): 1,262 nM,
Melan-A/MART-126–35 (HLA-A*02:01):
7,600 nM, or MAGE-A1161–169 (HLA-
A*01:01): 165 nM, as predicted by
Immune Epitope Database Analysis
Resource. Peptides predicted with high
affinity have rarely been described as
T cell epitopes. Although it is possible
that some of these peptides are not
generated (processed and presented), it
is more likely that these T cells have
been deleted during negative selection in
the thymus, if one assumes that with
increasing pMHC affinity the immunoge-
nicity of the epitope and the risk of auto-
immunity also increase. Thus, the best,
but also the most dangerous, epitopes
as targets for T cell therapy may not yet
be known. Conversely, cancer vaccines
targeting self-TA face the difficulty of not
only relying on T cells, which survived
central tolerance, but also targeting epi-
topes of low pMHC affinity.
A critical issue in this study is the source
of the TCRs expressed by the transgenic
TE cells and whether the TA is of self or
non-self origin. The TCRs specific for
high-affinity pMHC (SIY, ovalbumin, andl 23, April 15, 2013 ª2013 Elsevier Inc. 429
Figure 1. Tripartite Molecular Interaction Influences whether T Cells
Reject Large Established Tumors or Select Escape Variants
Top: the range of affinities of the T cell receptor (TCR) to peptide/MHC I com-
plexes (pMHC) is narrow (1–100 mM). TCRs specific for self-antigens (tolerant
repertoire) tend to have lower affinity, whereas TCRs specific for non-self
antigens (non-tolerant repertoire) tend to have a higher affinity for their cognate
pMHC.
Middle: the range of pMHC affinities is broad (<1 nM to >20,000 nM). Indicated
are pMHC affinities used in Engels et al. (2013) relative to therapeutic outcome.
With decreasing pMHC affinity, adoptive T cell therapy leads from rejection to
regression/recurrence of antigen (Ag) loss variants and then to recurrence
without antigen loss (*or therapy failure). Note the gap in affinities between
the different therapeutic outcomes, e.g., between 4.2 and 186 nM. For a variety
of human tumor antigens, T cell epitopes are predicted within this range,
raising the question of the cut-off value of ‘‘rejection epitopes’’.
Bottom: the relationship between pMHC affinity and success of T cell therapy
is shown. If the TCR to pMHC affinity is optimal (red line), increasing pMHC
affinity will (from a certain threshold onward) lead to an increase of success
in therapy (relapse free survival) until a plateau (100% success) is attained.
Black line, hypothetical graph illustrating that not only pMHC affinity but also
TCR affinity decides over rejection versus relapse.
Cancer Cell
Previewstyrosinase) were derived from
an antigen-free (nontolerant)
host, whereas the TCR spe-
cific for low affinity pMHC
(gp100) was isolated from
an antigen-positive (tolerant)
host. Even if the human
gp100 peptide (sharing six of
nine amino acids with mouse
gp100) was of non-self origin
for the mouse T cells, it is un-
clear whether the TCR affinity
for this pMHC is comparable
to those TCRs from the non-
tolerant repertoire, recog-
nizing pMHC with high affin-
ity. Thus, one cannot exclude
that a higher affinity of the
TCR for pMHC, isolated from
the non-tolerant repertoire
and used for TCR gene
therapy, can, at least partially,
compensate for lower pMHC
affinity.
The experiments targeting
the self-TA gp100 with low
pMHC affinity reflected a
clinical TCR gene therapy
trial with transient autoimmu-
nity and little efficacy (John-
son et al., 2009), indicating
that the experimental cancer
model can predict clinical
success/failure. The experi-
ments targeting tyrosinase,
another melanocyte differ-
entiation antigen with high
pMHC affinity, self for the
host and non-self for the TE
cells resulted in tumor rejec-
tion and autoimmune vitiligo.
However, the severity of auto-
immunity may be difficult to
predict using the mouse
model and depends greatly
on the respective self-TA.
As noted earlier, unforeseen
expression of self-TA on rare
vital cells is an unresolved
problem when using TCRs
from the nontolerant reper-
toire that target TA with
assumed restricted tissueexpression such as differentiation or
cancer-testis antigens (Blankenstein
et al., 2012). TCR from the nontolerant
repertoire can be biological weapons
(Bos et al., 2008). However, we hypothe-
size that the thymus overshoots in delet-430 Cancer Cell 23, April 15, 2013 ª2013 Elsing more T cells than necessary. The
repertoire is still large enough to cope
with most pathogens, and the evolu-
tionary priority was to minimize the risk
of autoimmunity. There may be a useful
compartment of T cells against self-TA inevier Inc.the nontolerant repertoire
that cause little or no damage
but are nevertheless deleted.
Nonetheless, targeting so-
matically mutated non-self
TA would clearly be advanta-
geous (Anders and Blanken-
stein, 2013; Schreiber and
Rowley, 2008).
The study by Engels et al.
(2013) is important, because
it teaches us which epitopes
not to target and how relevant
experimental cancer models
can be. However, a high affin-
ity pMHC is not a good target
per se. Too-low TA expres-
sion, inefficient processing
and peptide presentation
or posttranslational modifi-
cation of the peptide could
impede T cell therapy
despite targeting a high-
affinity pMHC. TAs are not
always homogenously ex-
pressed within the tumor. In
this case, the mechanism of
tumor stroma destruction
and the extent of bystander
elimination of escape variants
need to be better understood.
Together, suitable TAs and
particularly epitopes as tar-
gets in adoptive T cell therapy
can and should be selected
based on rational experi-
mental models before clinical
tests are done.
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Cancer stem cells (CSCs) drive solid tumor formation. In this issue of Cancer Cell, Zhao and colleagues in-
dentify the calcium channel a2d1 subunit as a new functional hepatocellular carcinoma (HCC) CSC
biomarker, which is vital for CSC biology as blocking a2d1 in combination with doxorubicin treatment hinders
HCC tumor formation.Hepatocellular carcinoma (HCC) ac-
counts for 90% of primary liver cancers
and is the third most common cause of
cancer-related deaths worldwide (Ed-
wards et al., 2010). Unlike most other
carcinomas, where mutations in specific
oncogenes or tumor suppressors drive
tumor initiation and progression, the
majority of HCCs are multifactorial and
primarily due to infections with hepatitis
B virus (HBV) or hepatitis C virus (HCV).
However, worldwide cases of nonviral
HCC are on the rise due to growing
numbers of patients with metabolic liver
diseases (Alberti et al., 2005; Van Thiel
and Ramadori, 2011). This multi-causality
makes identification and subsequent
targeting of a common HCC-specific
alteration or even a cell-of-origin virtually
impossible. Fortunately, where con-
sensus does exist is in the concept that
the majority of HCC arise from a subpop-
ulation of cancer cells referred to as tu-
mor-initiating cells (TICs) or cancer stem
cells (CSCs) (Majumdar et al., 2012).
Thus, identifying and therapeutically tar-
geting these cells represents a more
feasible approach for treating HCC
regardless of the underlying cause.
CSCs are believed to possess stem
cell-like properties such as unlimitedself-renewal, exclusive in vivo tumorige-
nicity, and subsequent generation of
differentiated progeny recapitulating the
parental tumor phenotype (Figure 1). Evi-
dence for their existence in several solid
tumors has been experimentally demon-
strated (reviewed in Hermann et al.,
2010). For HCC, cells expressing diverse
markers such as CD133, CD13, CD24,
CD90, and EpCAM as well as cells
defined as the side population have all
been demonstrated to bear CSC charac-
teristics. Apparently, the utility of these
different markers across established cell
lines and primary tumors varies signifi-
cantly, and their suitability for therapeutic
targeting has not been extensively
evaluated. Therefore, the identification of
markers, preferably a single marker, for
efficient isolation of CSCs from the com-
plex tumor cellular environment across
different HCC tissues is still critically
needed.
In this issue of Cancer Cell, Zhao et al.
(2013) report that HCC CSCs can be spe-
cifically isolated with a new antibody
(1B50-1) identified using awhole-cell sub-
tractive immunization approach that rec-
ognizes the isoform 5 of the cell surface
calcium channel a2d1 subunit. 1B50-1
binds a subpopulation of HCC cells, here-after termed a2d1+ cells, exhibiting stem
cell-like properties, such as increased
invasiveness, expression of stem cell-
associated genes (OCT4, SOX2, NANOG,
and BMI1), increased self-renewal, and
the ability to give rise to both a2d1+ and
a2d1– cells. More importantly, the authors
showed that subcutaneously injected
a2d1+ cells from cell lines and primary
HCC tumors were more tumorigenic in
NOD/SCID mice compared to their a2d1–
counterparts. Although the increased
tumorigenic potential of a2d1+ cells was
evident with as little as 103 cells, limiting
dilution assays (injection with less than
100 cells were not performed) revealed
that not all a2d1+ cells were tumorigenic
(TIC frequency in primary cases: 1 in 458
[748-281]), and higher numbers of a2d1–
cells were also capable of forming tumors
(TIC frequency: 1 in 1,957 [3,785-1,012])
(calculated from Table 1 in Zhao et al.,
2013). Therefore, a2d1+ cells from primary
tumors were enriched for CSCs 4-fold.
Unlike many normal tissues where a
stringent unidirectional hierarchy and
strict balanced asymmetric division pre-
serve tissue integrity (Jan and Jan,
1998), data in solid tumors are generally
not as clear cut. On the one hand, this
might be related to our still limited abilityl 23, April 15, 2013 ª2013 Elsevier Inc. 431
